Chiesi (Germany)

<b>Background:</b> Clinical trials have shown significant therapeutic benefits of extrafine formulation single-inhaler triple therapy (efSITT) consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium in the treatment of patients with asthma. The impact of efSITT on lung function in patients with asthma in a real-life setting is yet to be assessed. <b>Aims and objectives:</b> The TriMaximize study aims to provide the characteristics, therapy pathways and health-related outcomes of patients with moderate-to-severe asthma prescribed efSITT in real-world practice. We present an interim analysis of the changes in lung function in the first 284 patients from Germany, United Kingdom, Austria, and Denmark after three months of treatment with efSITT. <b>Methods:</b> This is a multicenter, multinational, prospective, observational study following patients with asthma for 1―3 years. Clinical data are collected from patients’ medical records. <b>Results:</b> The majority (79.7%) of patients were on prior ICS/LABA treatment, and 20.3% on prior ICS/LABA/LAMA. <b>Conclusions:</b> Our data show a significant improvement in lung function and specific airway resistance in patients with moderate-to-severe asthma after three months of treatment with efSITT following a switch from ICS/LABA or ICS/LABA/LAMA.

<b>Background:</b> Randomized controlled trials have shown significant clinical benefits of extrafine single-inhaler triple therapy (efSITT) consisting of beclometasone dipropionate/formoterol fumarate/glycopyrronium in the treatment of asthmatics not adequately controlled with ICS/LABA, and with ≥1 exacerbation in the last year. <b>Aims and objectives:</b> The TriMaximize study aims to provide a real-world view of the characteristics and therapy pathways in patients with moderate-severe asthma prescribed efSITT in real-world practice, and to characterize the effects of efSITT on health-related outcomes. Here, we present an interim analysis of the changes in health-related quality of life (HRQoL) in the first 181 patients from Germany after 3 months of treatment with efSITT. <b>Methods:</b> This is a multicenter multicountry prospective non-interventional study aiming to enroll 2,600 asthmatics prescribed efSITT for 12 to 36 months in a real-world practice. Changes in HRQoL are measured by the Mini Asthma Quality of Life Questionnaire (Mini AQLQ). <b>Results:</b> The majority (73.7%) were on prior ICS/LABA treatment, and 23.2% on prior ICS/LABA/LAMA. Mean Mini AQLQ score at baseline was 4.2 points. After 3 months of treatment with efSITT, mean change from baseline was 0.7 points (p&lt;0.0001) and 0.8 points (p&lt;0.0001) in the overall population and in patients on prior ICS/LABA combination, respectively, with both results exceeding the MCID of 0.5 points. <b>Conclusions:</b> TriMaximize is the first real-world study to report a significant improvement of HRQoL in patients with moderate-severe asthma switched from ICS/LABA or ICS/LABA/LAMA to efSITT.

Introduction: TriOptimize is the first real-world (RW) study collecting data from patients treated with extrafine single inhaler triple therapy (efSITT). Here, we present an interim analysis of changes in health-related quality of life (HRQoL) after 3 months treatment with efSITT. Methods: Changes in HRQoL measured by the COPD assessment test (CAT) were retrieved from health records of 1866 patients with moderate to severe COPD treated with efSITT (BDP/FF/G) for 3 months, stratified by COPD pre-therapy. Results: For patients previously treated with LABA/LAMA (n= 324), average CAT score improved after 3 months treatment with efSITT from 21.0 to 17.8 with -3.3 points (p Summary and Conclusion: TriOptimize is the first RW study to report a significant clinically meaningful improvement in HRQoL following a switch from ICS/LABA, LAMA/LABA or MITT to efSITT with BDP/FF/G in patients with moderate to severe COPD.

In the present study, patients with asthma were interviewed with regard to their treatment adherence. It was shown that adherence is significantly influenced by age, occupation, quality of information about the disease and interest of the patient in disease, mode of action and use of the inhalation device. Younger, working patients who do not feel "completely adequately" informed are more likely to be not-adherent. Each aspect should be noted separately.The characterization enables forming target groups for appropriate counselling initiatives in pulmonology practice and allows the effectiveness of the measures to be examined. The results confirm the importance of doctor/patient communication for achieving a high level of adherence and thus therapeutic success.It is suggested that, in addition to questionnaires already in use, asthma patients should be given the following questions in writing during routine monitoring of therapy; based on the results of the survey, the extent of advice necessary can be determined -Do you feel sufficiently informed about your illness? -Do you feel sufficiently informed about the effect of the drug therapy? -Do you feel sufficiently informed about the handling of the inhalation drugs? -Are you satisfied with the handling of your inhalation medication? The following options to answer the questions should be available: completely - mainly - somewhat - not at all. There were significant differences in adherence between patients who were completely satisfied with the handling of their device and those that were not. However, there was no significant difference between the devices. Therefore, the same therapy adherence can be predicted for all devices when the device is suitable for the patient and also provides complete satisfaction in handling. Since it is the subjective perception of patients, the data show significant differences between study centres. These were mirrored in a blind benchmark to stimulate improvements.